Esophageal cancer research focuses on neoadjuvant treatment sequencing, adjuvant immunotherapy, and histology-specific systemic options.
ACT-GI was a multicenter, randomized, double-blind, placebo-controlled, investigator-initiated phase II trial at four US sites. Forty-seven adults receiving chemotherapy for gastrointestinal cancers with persistent chemotherapy-induced thrombocytopenia (platelet count ≤85 × 10⁹/L on day 1 of a scheduled cycle despite adequate recovery time) were assigned 1:1 to oral avatrombopag (n = 23) or placebo (n = 24). The primary endpoint, a composite of platelet recovery to ≥100 × 10⁹/L, completing one on-study chemotherapy cycle without thrombocytopenia-related dose reduction or delay, and ≥100 × 10⁹/L at the start of the next cycle, was met by 16 of 23 patients (70%; 95% CI, 47 to 87) with avatrombopag vs 4 of 24 (17%; 95% CI, 5 to 37) with placebo (Z = 3.67, P < .001).
A multicohort analysis of 589,766 adults aged 40 to 74 years without prior cancer, drawn from the Shanghai Men’s Health Study, the Shanghai Women’s Health Study and UK Biobank, estimated how much of the higher cancer incidence in males is attributable to 11 lifestyle factors and health conditions.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.